Document is current
Any future updates will be listed below
-
Authors
Reznik, Ed https://orcid.org/0000-0002-6511-5947
Voss, Martin H. https://orcid.org/0000-0003-0551-5807
Hakimi, A. Ari https://orcid.org/0000-0002-0930-8824
- License Information
-
More Information
Article History
First Online: 2 January 2026
Competing interests
: A.A.H. reports research support from Merck. M.H.V. has been an invited speaker for Ideology Health, WebMD, MedNet, Talemhealth, Onclive, Axiom, Clinical Care Options, Targeted Oncology and Mashup Media; has been on the advisory board of Arcus Biosciences, Aveo, Calithera, Eisai, Exelixis, Genentech, Kura Oncology, Merck, MICU Rx, NiKang Therapeutics and Oncorena; has received research support from Merck; has been a principal investigator on research funded by Astra Zeneca, BMS, Calithera, Exelixis, Genentech, Merck, NiKang Therapeutics Pfizer, Regeneron and Roche; has recieved sponsorship/funding from Exelixis, Eli Lilly, Pfizer and Regeneron; and has had an advisory role for Affimed, Aravive, onQuality, Immunitybio, Astra Zeneca, Mertelsmann Foundation, Genetech, Merck and Nikang Therapeutics. E.R. reports no competing interests.
